New trial data has shown that liraglutide (sold as Novo Nordisk’s Victoza) can significantly reduce the risk of experiencing a major cardiovascular event. The results came from an international trial following more than 9,300 high-risk adults living with type 2 diabetes. Participants were examined for five years and were randomly assigned to one of two groups: one that received liraglutide and one that received a placebo.
The findings showed that when patients received liraglutide, the risks of cardiovascular death, nonfatal stroke, and myocardial infarction were significantly reduced. The safety profile was also consistent with previous trials involving liraglutide.
These findings were published on Medscape Medical News on March 4, 2016.